The head of Novartis’ big generics division Sandoz has abruptly handed in his walking papers in a move that will immediately reignite speculation that CEO Vas Narasimhan may be prepping a spinoff plan for the struggling group as the parent organization concentrates on developing new drugs.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,800+ biopharma pros who read Endpoints News by email every day.Free Subscription